Suscribirse

Endoplasmic reticulum stress inhibitor may substitute for sleeve gastrectomy to alleviate metabolic dysfunction-associated steatotic liver disease - 03/12/23

Doi : 10.1016/j.clinre.2023.102229 
Erli Pei a, Hui Wang a, Zhihong Li b, Xiaoyun Xie c, Li Cai d, , Moubin Lin a,
a Department of General Surgery, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China 
b Department of General Surgery, Zhoupu Hospital, Shanghai, China 
c Department of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China 
d Department of Science and Research, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China 

Corresponding authors.

Highlights

HFD-induced ERS led to the dysfunction of FGF21 signal transduction.
Bariatric surgery and ERS inhibition might rescue the FGF21 signaling dysfunction.
ERS inhibitors might be used as a treatment for MASLD.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming the most common form of chronic liver disease worldwide. We explored the potential mechanisms responsible for the protective role of sleeve gastrectomy (SG) on MASLD in a high-fat diet (HFD) rat model.

Methods

Rats were fed with HFD for 12 weeks to generate MASLD model that were subjected to SG or sham surgery. The endoplasmic reticulum stress (ERS) inhibitor 4-phenylbutyric acid (4-PBA) was injected intraperitoneally every day for 4 weeks after surgery to identify the impact of ERS.

Results

The MASLD rat model was generated successfully, as indicated by significant upregulation of metabolic parameters. Fibroblast growth factor 21 (FGF21) and ERS-related proteins were increased in HFD rats, while expression of fibroblast growth factor receptor 1 was decreased as expected. An HFD also induced swelling and blurring of the endoplasmic reticulum and mitochondria in hepatocytes, and the above transformation could be relieved by SG and 4-PBA. SG and an ERS inhibitor both inhibited MASLD, but their combined treatment had no additional benefit.

Conclusions

Dysfunction of the FGF21 signaling pathway and hepatic steatosis and inflammation could be induced by an HFD, potentially causing MASLD. Bariatric surgery and ERS inhibition could alleviate MASLD by relieving ERS-mediated impairment of FGF21 signal transduction. These findings provide a new insight into the use of ERS inhibitors to treat MASLD, especially in patients who prefer to avoid surgery.

El texto completo de este artículo está disponible en PDF.

Keywords : Sleeve gastrectomy, Endoplasmic reticulum stress, Fibroblast growth factor 21, Metabolic dysfunction-associated steatotic liver disease, Endoplasmic reticulum stress inhibitor


Esquema


© 2023  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 47 - N° 10

Artículo 102229- décembre 2023 Regresar al número
Artículo precedente Artículo precedente
  • Serum vitamin D is associated with ultrasound-defined hepatic fibrosis
  • Rong Jiang, Yichao Zhou, Lei Han, Zhen Hong
| Artículo siguiente Artículo siguiente
  • Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways
  • P. Tamilmani, V. V. Sathibabu Uddandrao, P. Chandrasekaran, G. Saravanan, Parim Brahma Naidu, S. Sengottuvelu, S. Vadivukkarasi

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.